Back

Equal performance of the subcutaneous and transvenous implantable cardioverter defibrillator across all age groups in the PRAETORIAN trial

30 August 2024 (15:00 - 15:40)
Organised by: Logo
Congress Presentation Part of: Subcutaneous and extravascular defibrillators: already mainstream? Device Treatment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Miss Shari Pepplinkhuizen

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Defibrillation success with a second generation intercostal extravascular ICD lead and commercially available left pectoral pulse generator
Doctor M. Burke (Chicago, US)
Abstract Slides Video
Presentation thumbnail
A comparative analysis of conduction system pacing and biventricular pacing in patients undergoing atrioventricular node ablation: a systematic review and meta-analysis
Doctor H. Eldeeb (Bristol, GB)
Abstract Slides Video
Presentation thumbnail
Sex differences in shocks and device-related complications in subcutaneous implantable-cardioverter defibrillator patients
Ms J. De Veld (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Antithrombotic therapy and the risk of pocket hematoma after subcutaneous implantable cardioverter-defibrillator implantation
Miss S. Pepplinkhuizen (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
long term follow up of Implantable Cardioverter Defibrillators (ICD) in hypertrophic cardiomyopathy: is subcutaneous the way forward?
Mr C. Monkhouse (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Subcutaneous and extravascular defibrillators: already mainstream?

The Event

Event poster

ESC Congress 2024

30 August 2024 15:00 CET
You may be interested in
thumbnail
Congress Session
Recent advances in implantable cardioverter defibrillator therapy
thumbnail
Congress Presentation
PRAETORIAN/ATLAS: Inappropriate shock with S-ICD vs. transvenous ICD
thumbnail
Congress Session
'Shocking' news on implantable cardioverter defibrillators

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources